BridgeMD
New treatment option for Advanced Solid Tumors
Official title JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration
ClinicalTrials.gov ID: NCT06973564
What this study is testing
What is JAB-23E73?
JAB-23E73 is an investigational medicine, given as a pill taken by mouth, being studied as a potential treatment for advanced solid tumors.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study is to evaluate the safety and tolerability of pan-KRAS inhibitor JAB-23E73 in adult participants with advanced solid tumors
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Written informed consent.
- Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).
- Histologically or cytologically confirmed locally advanced or metastatic solid tumors that are not suitable for curative interventions.
- Patients must have KRAS alterations.
- Participants are required to provide an archived tumor sample.
You likely can't join if
- Inability to swallow oral medications, or presence of gastrointestinal dysfunction or gastrointestinal disorders that may significantly alter the...
- Patients who have previously been treated with KRAS G12C inhibitors, KRAS G12D inhibitors, or pan/multi-KRAS inhibitors.
- Known serious allergy to JAB-23E73 or excipient.
- Patients with primary central nervous system tumors.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures or medical intervention.
- QT interval\>470 msec.
See the full eligibility criteria
- Written informed consent.
- Participant must be ≥18 years of age at the time of signing the Informed Consent Form (ICF).
- Histologically or cytologically confirmed locally advanced or metastatic solid tumors that are not suitable for curative interventions.
- Patients must have KRAS alterations.
- Participants are required to provide an archived tumor sample.
- Patients with a life expectancy ≥3 months.
- ECOG performance status score of 0 or 1.
- Patients must have at least one measurable lesion as defined by RECIST v1.1.
- Inability to swallow oral medications, or presence of gastrointestinal dysfunction or gastrointestinal disorders that may significantly alter the absorption of the study drug.
- Patients who have previously been treated with KRAS G12C inhibitors, KRAS G12D inhibitors, or pan/multi-KRAS inhibitors.
- Known serious allergy to JAB-23E73 or excipient.
- Patients with primary central nervous system tumors.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures or medical intervention.
- QT interval\>470 msec.
- LVEF ≤50% assessed by ECHO or MUGA.
The study team makes the final eligibility decision.
Where it's taking place
- Rochester, Minnesota, United States
- St Louis, Missouri, United States
- Cleveland, Ohio, United States
- Salt Lake City, Utah, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Rochester, Minnesota, United States; St Louis, Missouri, United States; Cleveland, Ohio, United States; Salt Lake City, Utah, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.